

Premier Health Insuring Corporation

POLICY AND PROCEDURE MANUAL

Policy Number: MP.004.PC
Last Review Date: 11/12/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

MP.004.PC - Rotavirus Vaccine

This policy applies to the following line(s) of business:

- ✓ Premier Health Insuring Corporation MA – DSNP

Premier Health Insuring Corporation considers Rotavirus Vaccine medically necessary for the following indications:

The rotavirus vaccine is covered under the routine Preventive Immunization Guidelines for Children:

1. RotaTeq® - infants should receive three doses of this vaccine—at 2 months, 4 months, and 6 months of age (6-32 weeks in children)
2. Rotarix® - Infants should receive two doses of this vaccine—at 2 months and 4 months of age (6-24 weeks in children)

Limitations:

- The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated for infants aged 15 weeks, 0 days or older
- The maximum age for the final dose in the series is 8 months, 0 days
- Spina Bifida

Background

Rotavirus gastroenteritis is the most common cause of severe dehydrating diarrhea in infants and young children, especially in developing countries. It accounts for 2 million hospital visits and 500,000 pediatric deaths each year worldwide. The Centers for Disease Control and Prevention (CDC) report that rotavirus can cause severe watery diarrhea, vomiting, fever, and abdominal pain.

RotaTeq® and Rotarix® are oral, liquid vaccines, which are part of the routine childhood immunization program. They provide protection against five serotypes of rotavirus, including serotypes G1, G2, G3, G4 and P1.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
90460	Immunization administration through 18 years of age via any route of administration with counseling by physician or other qualified

MP.004.PC - Rotavirus Vaccine

Policy Number: MP.004.PC
Last Review Date: 11/12/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

	health care professional; first or only component of each vaccine or toxoid administered
90461	Immunization administration through 18 years of age via any route of administration with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use
90681	Rotavirus vaccine, human attenuated, 2 dose schedule live, for oral use

References

1. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years — United States, 2015. Available at: <http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf>
2. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine, Pediatrics. 2009 May; 123(5): 1412-1420 doi: 10.1542/peds.2009-0466. <http://pediatrics.aappublications.org/content/123/5/1412.full>
3. Centers for Disease Control and Prevention (CDC). CDC Features – Protect your child from Rotavirus Disease. Last updated: Jan. 13, 2015. Accessed 10/27/2015. <http://www.cdc.gov/Features/Rotavirus/index.html>
4. Centers for Disease Control and Prevention (CDC). Morbidity and Mortality Weekly Report (MMWR). Prevention of Rotavirus Gastroenteritis Among Infants and Children; Recommendations of the Advisory Committee on Immunization Practices (ACIP). February 6, 2009. <http://www.cdc.gov/mmwr/PDF/rr/rr5802.pdf>
5. Centers for Disease Control and Prevention (CDC) Vaccine Information Statements (VIS). Provider Information: Rotavirus VIS. Edited: 08/26/2013. <http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rotavirus-hcp-info.html>
6. Cortese MM, Dahl RM, Curns AT et al. Protection Against Gastroenteritis in US Households With Children Who Received Rotavirus Vaccine. J Infect Dis. 2015

MP.004.PC - Rotavirus Vaccine

Policy Number: MP.004.PC
Last Review Date: 11/12/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

- Feb 15;211(4):558-562. doi: 10.1093/infdis/jiu503. Epub 2014 Sep 18.
<http://www.ncbi.nlm.nih.gov/pubmed/25234721>
7. FDA News: FDA Approves New Vaccine To Prevent Gastroenteritis Caused by Rotavirus. Issued: 04/03/2008.
<http://www.fda.gov/newsevents/newsroom/pressannouncements/2008/ucm116875.htm>
 8. Merck & Co., Inc. Rotateq (Rotavirus Vaccine, Live, Oral, Pentavalent). Prescribing Information. Initial U.S. Approval 2006. Revised: 11/2014. uspi-v260-os-1411r021 Available at:
http://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf
 9. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine, N Engl J Med. 2001; 344:564-572.
<http://www.nejm.org/doi/pdf/10.1056/NEJM200102223440804>
 10. National Institutes of Health. National Library of Medicine (NLM). MedlinePlus- Rotavirus Infections. Last updated: Feb. 10, 2015.
<http://www.nlm.nih.gov/medlineplus/rotavirusinfections.html>
 11. Parashar UD, Holman RC, Clarke MJ, et al. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: Surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis. 1998; 177:13-17. <http://www.ncbi.nlm.nih.gov/pubmed/9419164>
 12. Strikas RA. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):93-94.
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6404a5.htm>
 13. United States Food and Drug Administration (FDA): Vaccines, Blood & Biologics- Rotarix. Manufacturer: GlaxoSmithKline Biologicals. Last updated: 12/04/2014.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm133920.htm>
 14. United States Food and Drug Administration (FDA): Vaccines, Blood& Biologics- RotaTeq. Manufacturer: Merck & Co, Inc. Last updated: 12/02/2014.
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm>
 15. Velasquez DE, Parashar UD, Jiang B. Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview. Infect Genet Evol. 2014 Dec;28:561-571. doi: 10.1016/j.meegid.2014.10.008. Epub 2014 Oct 16.
<http://www.ncbi.nlm.nih.gov/pubmed/25460825>
 16. World Health Organization (WHO). Rotavirus Vaccine - WHO position paper, January 2013. Wkly Epidemiol Rec. 2013 Feb; 88(5): 49-64.
<http://www.who.int/wer/2013/wer8805.pdf?ua=1>

MP.004.PC - Rotavirus Vaccine

Policy Number: MP.004.PC
Last Review Date: 11/12/2015
Effective Date: 01/01/2016
Renewal Date: 01/01/2017

Disclaimer:

Premier Health Insuring Corporation medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Premier Health Insuring Corporation and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Premier Health Insuring Corporation reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.